EMBC - Embecta Corp logo

Embecta Corp

EMBC
Net -8.28%top 1%Rev -5.71%top 1%1Y
Compare EMBC Hold

Embecta Corp. designs and manufactures medical devices for diabetes management, including pen needles, syringes, and safety injection devices. The company sells primarily to wholesalers and distributors, focusing on improving health and wellbeing for diabetics.

โš•๏ธ Healthcare NASDAQ Listed 2022 $ USD
$1,000 invested 1 year ago โ†’$409today

Score Overview

1 Year
Scoreโ€”
Net Growth-8.28%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-5.71%
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-60.87%
Net Trend50%
Net Income Consistency
Rev Growth-9.81%
Rev Trend25%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Embecta Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. EMBC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-02
$ 5.65โ€”
1 Year2025-10-02
$ 13.81-59.07%
All Time2022-04-01
$ 26.39-78.59%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1.01B$ 87M$ 214M
2025$ 1.08B$ 95M$ 225M
2024$ 1.12B$ 78M$ 267M
2023$ 1.12B$ 70M$ 326M
IPO2022$ 1.12B$ 223M$ 330M
EMBC - Embecta Corp logo

Embecta Corp fundamental performance

Across Embecta Corp's full reported history, from 2022 to 2025, revenue declined from $ 1.12B to $ 1.08B and net income declined from $ 223M to $ 95M. Revenue increased in 25% of the years measured; net income in 50%.

Membership

Explore EMBC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies